ArticleJAMA2024
Serum Urate and Recurrent Gout.
Article in JAMA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 36 citations in OpenAlex.
- Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout.Annals of the rheumatic diseases · 2024Trial
- Association of hyperuricemia with valvular heart disease and the modifying effect of obesity.The Korean journal of internal medicine · 2026Article
- Real-world effectiveness and safety of firsekibart versus compound betamethasone in frequent gout flares: a multicenter retrospective study.Clinical rheumatology · 2026Article
- Article
- Preinfusion Glucocorticoid Reduction and Elimination in Patients With Uncontrolled Gout on Pegloticase and Methotrexate: A Case Series.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2026Article
- Ultrasound-Assisted Soaking Facilitates Purine Dissolution from Soybean Powder: Development and Preliminary Application of Low-Purine Soybean Powder.Foods (Basel, Switzerland) · 2026Article
- Gout Flare in Hospitalized Patients: Risk Factors and the Impact of Allopurinol Management.Cureus · 2026Article
- Gut microbiota Lactobacillus johnsonii alleviates hyperuricemia by modulating intestinal urate and gut microbiota-derived butyrate.Chinese medical journal · 2026Article
- Spatiotemporal immune gradients in gout: immune response-driven activation of the NLRP3-IL-1β axis and its transition to trained immunity.Frontiers in immunology · 2026Review
- The Impact of Uncontrolled Gout on Healthcare Utilization and Health Outcomes for United States Veterans Affairs Patients.Rheumatology and therapy · 2025Article
- Article
- Importance of Considering the Gout Flare: Let's Learn to Walk and Chew Gum at the Same Time in Gout Clinical Trial Design.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Empirical dietary index for lower urate concentrations and risk of gout: evidence from cohort studies.The American journal of clinical nutrition · 2025Article
- Quality Care Assessment in Gout.Current rheumatology reports · 2025Review
- Metabolomic profiles underlying gout flares: a prospective study of people with gout.RMD open · 2025Article
- Weight Reduction and Target Serum Urate Level: A Longitudinal Study of Annual Medical Examination.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Short-Term Risk of Cardiovascular Events in People Newly Diagnosed With Gout.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Spatiotemporal landscape of kidney in a mouse model of hyperuricemia at single-cell level.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- The changing burden of gout in adults aged 70 and above based on the global burden of disease 2019.Frontiers in public health · 2025Article
- Delineating circulating lymphocyte subsets in the transition from gout remission to recurrence.Frontiers in immunology · 2025Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Importance: Approximately 12 million adults in the US have a history of gout, but whether serum urate levels can help predict recurrence is unclear. Objective: To assess associations of a single serum urate measurement with subsequent risk of acute gout flares and subsequent risk of hospitalizations for gout among patients in the UK with a history of gout. Design, Setting, and Participants: This retrospective study included patients with a history of gout identified from the UK between 2006 and 2010 who were followed up through Primary Care Linked Data medical record linkage until 2017 and through the Hospital Episode Statistics database until 2020. Exposures: Serum urate levels at enrollment. Main Outcome and Measure: Rate of recurrent acute gout, ascertained by hospitalization, outpatient, and prescription/procedure records, and adjusted rate ratios using negative binomial regressions. Results: Among 3613 patients with gout (mean age, 60 years; 3104 [86%] men), 1773 gout flares occurred over a mean follow-up of 8.3 years. Of these, 1679 acute gout flares (95%) occurred in people with baseline serum urate greater than or equal to 6 mg/dL and 1731 (98%) occurred in people with baseline serum urate greater than or equal to 5 mg/dL. Rates of acute gout flares per 1000 person-years were 10.6 for participants with baseline urate levels less than 6 mg/dL, 40.1 for levels of 6.0 to 6.9 mg/dL, 82.0 for levels of 7.0 to 7.9 mg/dL, 101.3 for levels of 8.0 to 8.9 mg/dL, 125.3 for urate levels of 9.0 to 9.9 mg/dL, and 132.8 for levels greater than or equal to 10 mg/dL. Rate ratio of flares were 1.0, 3.37, 6.93, 8.67, 10.81, and 11.42, respectively, over 10 years (1.61 [1.54-1.68] per mg/dL). Rates of hospitalization per 1000 person-years during follow-up were 0.18 for those with baseline serum urate less than 6 mg/dL, 0.97 for serum urate of 6.0 to 6.9 mg/dL, 1.8 for serum urate of 7.0 to 7.9 mg/dL, 2.2 for serum urate of 8.0 to 8.9 mg/dL, 6.7 for serum urate of 9.0 to 9.9 mg/dL, and 9.7 for serum urate greater than or equal to 10 mg/dL. Rate ratios of hospitalization for gout, adjusting for age, sex, and race were 1.0, 4.70, 8.94, 10.37, 33.92, and 45.29, respectively (1.87 [1.57-2.23] per mg/dL). Conclusions and Relevance: In this retrospective study of patients with a history of gout, serum urate levels at baseline were associated with the risk of subsequent gout flares and rates of hospitalization for recurrent gout. These findings support using a baseline serum urate level to assess risk of recurrent gout over nearly 10 years of follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.